SCHEDULE 13G/A: Baillie Gifford & Co. Maintains Significant 6.5% Stake in Recursion Pharmaceuticals

Baillie Gifford & Co. has filed an Amendment No. 5 to Schedule 13G, disclosing a 6.5% beneficial ownership stake in Recursion Pharmaceuticals, Inc. as of December 31, 2024.

Summary

• Baillie Gifford & Co., a UK-based investment adviser, filed an Amendment No. 5 to Schedule 13G.
• The filing reports their beneficial ownership in Recursion Pharmaceuticals, Inc. (CUSIP: 37611X100).
• As of December 31, 2024, Baillie Gifford & Co. beneficially owns an aggregate of 24,864,058 shares of Recursion Pharmaceuticals' Common Stock.
• This ownership represents 6.5% of the total class of securities.
• Baillie Gifford & Co. holds sole voting power over 24,786,819 shares and sole dispositive power over 24,864,058 shares.
• The securities are held by Baillie Gifford & Co. and/or its investment adviser subsidiaries on behalf of various investment advisory clients, including investment companies, employee benefit plans, pension funds, or other institutional clients.

Sentiment

Score: 6

Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G Amendment No. 5) indicating a significant, continued stake by a major investment adviser. It does not contain operational or financial performance data to assess sentiment beyond the fact of institutional holding, which is generally a neutral to slightly positive signal.

Positives

• A major institutional investment adviser, Baillie Gifford & Co., maintains a significant 6.5% beneficial ownership stake in Recursion Pharmaceuticals, Inc., indicating continued institutional interest and confidence in the company.

Negatives

• The document does not contain information regarding the operational or financial performance of Recursion Pharmaceuticals, Inc., which would be necessary to assess potential negatives.

Risks

• The Schedule 13G filing itself does not detail specific risks related to Recursion Pharmaceuticals, Inc.'s operations or financial health; it is solely a disclosure of beneficial ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which may contribute to investor confidence.
• Company Management: Awareness of a large institutional holder's stake, which may influence strategic decisions or engagement.

Key Dates

Keywords

Recursion Pharmaceuticals, Baillie Gifford & Co., Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Institutional Investor